Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 10 » Issue 1

Proteoglycan 4 is a diagnostic biomarker for COPD

Authors Lee K, Chuang H, Chen T, Liu W, Su C, Feng P, Chiang L, Bien M, Ho S

Received 22 June 2015

Accepted for publication 18 August 2015

Published 18 September 2015 Volume 2015:10(1) Pages 1999—2007


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Professor Hsiao-Chi Chuang

Peer reviewer comments 7

Editor who approved publication: Dr Richard Russell

Kang-Yun Lee,1,2 Hsiao-Chi Chuang,1,3 Tzu-Tao Chen,1 Wen-Te Liu,1,3 Chien-Ling Su,1,3 Po-Hao Feng,1,2 Ling-Ling Chiang,1,3 Mauo-Ying Bien,3,4 Shu-Chuan Ho3

1Division of Pulmonary Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan; 2Department of Internal Medicine, School of Medicine, 3School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei, Taiwan; 4Division of Pulmonary Medicine, Department of Internal Medicine, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan

Introduction: The measurement of C-reactive protein (CRP) to confirm the stability of COPD has been reported. However, CRP is a systemic inflammatory biomarker that is related to many other diseases.
Objective: The objective of this study is to discover a diagnostic biomarker for COPD.
Methods: Sixty-one subjects with COPD and 15 healthy controls (10 healthy non-smokers and 5 smokers) were recruited for a 1-year follow-up study. Data regarding the 1-year acute exacerbation frequency and changes in lung function were collected. CRP and the identified biomarkers were assessed in the validation COPD cohort patients and healthy subjects. Receiver operating characteristic values of CRP and the identified biomarkers were determined. A validation COPD cohort was used to reexamine the identified biomarker. Correlation of the biomarker with 1-year lung function decline was determined.
Results: Proteoglycan 4 (PRG4) was identified as a biomarker in COPD. The serum concentrations of PRG4 in COPD Global initiative for chronic Obstructive Lung Disease (GOLD) stages 1+2 and 3+4 were 10.29 ng/mL and 13.20 ng/mL, respectively; 4.99 ng/mL for healthy controls (P<0.05); and 4.49 ng/mL for healthy smokers (P<0.05). PRG4 was more sensitive and specific than CRP for confirming COPD severity and acute exacerbation frequency. There was no correlation between CRP and PRG4 levels, and PRG4 was negatively correlated with the 1-year change in predicted forced vital capacity percent (R2=0.91, P=0.013).
Conclusion: PRG4 may be a biomarker for identification of severity in COPD. It was related to the 1-year forced vital capacity decline in COPD patients.

Keywords: C-reactive protein, exacerbation, inflammation, lung function decline

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Other articles by this author:

Proteasome activity related with the daily physical activity of COPD patients

Lee KY, Chen TT, Chiang LL, Chuang HC, Feng PH, Liu WT, Chen KY, Ho SC

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1519-1525

Published Date: 22 May 2017

The relationship between anthropometric indicators and walking distance in patients with chronic obstructive pulmonary disease

Ho SC, Hsu MF, Kuo HP, Wang JY, Chen LF, Lee KY, Chuang HC

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1857-1862

Published Date: 8 September 2015

Low bone mineral density in COPD patients with osteoporosis is related to low daily physical activity and high COPD assessment test scores

Liu WT, Kuo HP, Liao TH, Chiang LL, Chen LF, Hsu MF, Chuang HC, Lee KY, Huang CD, Ho SC

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1737-1744

Published Date: 1 September 2015

Readers of this article also read:

Methotrexate-loaded lipid-core nanocapsules are highly effective in the control of inflammation in synovial cells and a chronic arthritis model

Boechat AL, Oliveira CP, Tarragô AM, Costa AG, Malheiro A, Guterres SS, Pohlmann AR

International Journal of Nanomedicine 2015, 10:6603-6614

Published Date: 22 October 2015

Mesenchymal stem cell therapy for osteoarthritis: current perspectives

Wyles CC, Houdek MT, Behfar A, Sierra RJ

Stem Cells and Cloning: Advances and Applications 2015, 8:117-124

Published Date: 28 August 2015

Molecular targets in arthritis and recent trends in nanotherapy

Roy K, Kanwar RK, Kanwar JR

International Journal of Nanomedicine 2015, 10:5407-5420

Published Date: 26 August 2015

Is increasing the dose of Entecavir effective in partial virological responders?

Erturk A, Adnan Akdogan R, Parlak E, Cure E, Cumhur Cure M, Ozturk C

Drug Design, Development and Therapy 2014, 8:621-625

Published Date: 29 May 2014

Clinical use of biologics in vasculitis syndromes

Paroli M

Biologics: Targets and Therapy 2012, 6:371-378

Published Date: 25 October 2012

Topical diclofenac in the treatment of osteoarthritis of the knee

Niklas Schuelert, Fiona A Russell, Jason J McDougall

Orthopedic Research and Reviews 2011, 3:1-8

Published Date: 6 February 2011

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010